secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apellis Pharmaceuticals, Inc. (APLS)
CIK:        0001492422
Form:       8-K
Filed at:   2025-07-01T23:59:59+00:00
Accession:  0001193125-25-153429
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Apellis enters $275M royalty buy-down with Sobi; reduces Aspaveli royalties 90%
-------------------------------------------------------------------------------

- Sobi pays Apellis $275M upfront; up to $25M more on EMA approval of Aspaveli for C3G and IC-MPGN.
- Royalty obligations under Collaboration Agreement reduced by 90% from closing, subject to cap of 1.45x payments made.
- Sixth Street lenders consent to deal; Apellis extends prepayment premium periods on credit facility by one year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1492422/000119312525153429/0001193125-25-153429-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1492422/000119312525153429/d940210d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-153429

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer